Spots Global Cancer Trial Database for A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Official Title: A PHASE 2, MULTI-CENTER, OPEN-LABEL, DUAL-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORLATINIB (PF-06463922) MONOTHERAPY IN ALK INHIBITOR-TREATED LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA
Study ID: NCT03909971
Conditions
Interventions
Study Description
Brief Summary: A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China
Detailed Description: This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy. * (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor. * (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing, China
Fujian Province Oncology Hospital, Fuzhou, Fujian, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Hunan Provincial Tumor Hospital/Division of Oncology, Changsha, Hunan, China
The first hospital of jilin university, Changchun, Jilin, China
Jilin Provincial Cancer Hospital, Changchun, Jilin, China
Tangdu Hospital of Fourth Military Medical University, Xi'an, Shanxi, China
Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China
West China Hospital, Sichuan University, Cancer center, Chengdu, Sichuan, China
The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Fifth Medical Center of PLA General Hospital, Beijing, , China
Beijing Chest Hospital, Capital Medical University, Beijing, , China
Guangdong Provincial People's Hospital, Guangzhou, , China
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, , China
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, , China
Shanghai Chest Hospital, Shanghai, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Zhongshan Hospital, Fudan University, Shanghai, , China
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
